中国医药科学2024，Vol.14Issue(10)：158-161,4.DOI:10.20116/j.issn2095-0616.2024.10.38
老年晚期非小细胞肺癌患者的免疫治疗效果观察
Observation of immunotherapy efficacy on elderly patients with advanced non-small cell lung cancer
梁淑芳1
作者信息
- 1. 山东省菏泽市牡丹人民医院肿瘤科,山东菏泽 247000
- 折叠
摘要
Abstract
Objective To investigate the efficacy and safety of immune checkpoint inhibitors(ICIS)in immunotherapy on elderly patients with non-small cell lung cancer(NSCLC).Methods A total of 50 patients with NSCLC admitted to and treated in Mudan People's Hospital in Heze City from January 2020 to July 2022 with complete follow-up data available were selected and divided into the observation group(n=28,age≥65 years)and the control group(n=22,age<65 years)according to their ages.Both groups were treated with programmed death protein-1(PD-1)inhibitor monoclonal antibody,and were followed up for more than half a year.The efficacy,adverse drug reactions(ADRs),and survival curves were compared between two groups.Results There was no statistically significant difference in the therapeutic efficacy of PD-1 inhibitor monoclonal antibody of patients between the two groups(P>0.05).There was no statistically significant difference in the number of cases of ADRs between the two groups during treatment(P>0.05).Conclusion The use of PD-1 inhibitor monoclonal antibodies for ICIS has achieved relatively good efficacy and safety in patients with NSCLC aged 65 and above,with similar efficacy and safety in young patients.关键词
免疫检查点抑制剂/程序性死亡蛋白-1抑制剂/非小细胞肺癌/老年Key words
Immune checkpoint inhibitors/PD-1 inhibitor/Non-small cell lung cancer/Elderly分类
医药卫生引用本文复制引用
梁淑芳..老年晚期非小细胞肺癌患者的免疫治疗效果观察[J].中国医药科学,2024,14(10):158-161,4.
